Aller au contenu principal
Accès ouvert déclaré 2026 article

Barrett's esophagus: How can we miss high-grade dysplasia/cancer?

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : be. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

10.1055/a-2781-6649 Detection of neoplasia in Barrett’s esophagus (BE) remains a persistent challenge despite major advances in endoscopic imaging and training. A substantial proportion of lesions are still overlooked during initial examinations, highlighting the multifactorial nature of diagnostic performance. Kako et al. should be congratulated for their thoughtful retrospective study of 91 patients with Barrett’s neoplasia (BN), of whom almost one-third were identified as having post-endoscopy Barrett’s neoplasia (PEBN). This multicenter work, covering two decades and six institutions, provides valuable insight into long-term surveillance quality and the determinants of early detection in a low-prevalence setting. BE remains far less prevalent in Japan than in Western countries, which inevitably limits clinical exposure and may influence diagnostic performance. A lower background prevalence also means that endoscopists encounter fewer Barrett’s cases in routine practice, reducing opportunities for pattern recognition and systematic audit. Volume, in itself, does not define expertise, but sustained exposure and repeated feedback are essential to maintain detection skills. Within this context, the modest overall number of patients identified in the study is understandable, although it underscores the challenge of achieving and measuring proficiency in low-prevalence settings. Given the 20-year inclusion period, the evolution of endoscopic technology, from standard-definition to high-definition (HD) systems and virtual chromoendoscopy, cannot be ignored. It would be valuable to know whether the retrospectively identified lesions were equally distributed across the HD and non-HD eras, and whether exposure errors were more frequent in examinations performed with earlier, lower-resolution systems. Kako et al. reported that in nearly two-thirds of cases, a visible lesion had, in fact, been present at the index endoscopy, suggesting that perceptual errors, rather than purely exposure failures, accounted for most missed neoplasia. This finding challenges the common assumption that undetected lesions are mainly the result of technical limitations. However, it should also be recognized that the review was based on still images rather than full video sequences, which inherently limits interpretation. Even though systematic photodocumentation appeared to have been performed, static images may not fully capture mucosal exposure or dynamic inspection quality. Recent European Society of Gastrointestinal Endoscopy (ESGE) quality recommendations emphasize the importance of structured photodocumentation during Barrett’s surveillance, including images of all landmarks and one picture per centimeter of Barrett’s length, as well as of any visible lesions [ 1 ]. Such systematic imaging not only facilitates external audit and teaching but also provides an objective basis for later review and performance assessment. A notable feature of the study is absence of systematic use of the Seattle biopsy protocol in Japan, where targeted biopsies remain the rule. In Western practice, this protocol remains the cornerstone of Barrett’s surveillance because it continues to provide most histologic diagnoses of dysplasia or early adenocarcinoma. Robust evidence supports its value: After targeted sampling of visible abnormalities, random four-quadrant biopsies every 2 cm along the Barrett’s segment detect dysplasia in 19.1%, compared with 2.6% when non-protocolized sampling is used (relative risk 6.27, 95% confidence interval [CI] 2.75–14.33) [ 2 ]. Despite this clear benefit, adherence in daily practice remains variable across studies and centers. In U.S. and European registries, compliance rarely exceeds 50%, whereas recent UK data show that dedicated Barrett’s lists achieve markedly higher guideline adherence and, consequently, a significantly higher dysplasia detection rate (6.3% vs 2.7%) than standard mixed lists [ 1 ] [ 3 ] [ 4 ]. This variability illustrates how organization and training directly influence quality. Systematic implementation of the Seattle protocol could represent one of the most effective and measurable approaches to reducing interval neoplasia, although this remains to be formally demonstrated. In the series by Kako et al., several of the “missed” prevalent lesions might have been histologically detected if random biopsies had been performed according to this standard. This study highlights how the quality of the index endoscopy largely determines subsequent management and outcomes in patients with BE. Both the ESGE and American Gastroenterological Association have recently updated their quality criteria for Barrett’s surveillance, emphasizing technical performance, mucosal visualization, documentation, and histologic sampling strategy [ 1 ] [ 3 ]. HD systems, now the accepted minimum standard, enhance detection of subtle mucosal abnormalities that standard imaging may miss [ 5 ]. Because the inclusion period of the current study extends over two decades, such equipment was not consistently available, and comparisons between early and late eras, therefore, should be interpreted with caution. Mucosal visualization is another critical determinant of diagnostic yield. The ESGE recommends use of simethicone and adequate washing to achieve a clear, bubble-free field, followed by formal assessment of mucosal visibility using a validated scoring system [ 1 ]. As in colonoscopy, one can only detect what is adequately exposed. Inspection time is equally important. Independent studies have demonstrated a direct correlation between the time spent inspecting the Barrett’s segment and the dysplasia detection rate [ 6 ] [ 7 ]. A practical benchmark is to dedicate at least 1 minute per centimeter of circumferential Barrett’s before starting systematic biopsies [ 1 ] [ 3 ]. Sequential inspection under white light with maximal luminal distension, followed by virtual chromoendoscopy, is now recommended as the standard technique for Barrett’s examination. The pull-through technique involves slow, continuous withdrawal of the endoscope through an insufflated esophagus to maintain mucosal distension and optimize exposure of all mucosal surfaces. The inspection sequence during Barrett’s surveillance typically combines complementary modalities. Careful withdrawal inspection under HD white light, followed by virtual chromoendoscopy, remains the recommended standard approach. Acetic acid may be used as an adjunct. Early prospective work demonstrated that acetic acid chromoendoscopy increased dysplasia detection (9.4% vs 3.6%) while reducing the number of random biopsies compared with the Seattle protocol [ 8 ]. The multicenter ABBA trial later confirmed the feasibility and safety of acetic acid-targeted biopsies but found no significant difference in dysplasia detection compared with the standard four-quadrant approach, despite a substantial reduction in biopsy burden [ 9 ] [ 10 ]. More recently, the large multicenter ACID trial conducted across Dutch community hospitals reported no additional benefit of acetic acid over meticulous high-quality white-light inspection in a standard surveillance setting (7.4% vs 7.1%, odds ratio 0.97, 95% CI 0.65–1.44) [ 11 ]. The high detection rate observed in the standard surveillance arm suggests that examinations were already performed to a high technical standard, which may explain the absence of incremental gain and in addition, low-grade dysplasia (LGD) was included as an outcome, which is often flat and only detected on random biopsies. Together, these studies indicate that the value of acetic acid lies primarily in optimizing lesion detection in less experienced hands, whereas in expert settings where careful pull-back inspection with white light and virtual chromoendoscopy is systematically performed, its incremental diagnostic benefit appears limited. Even when the Seattle protocol is meticulously applied during high-quality endoscopy, refe

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Barrett's esophagus: How can we miss high-grade dysplasia/cancer?
Date Crossref
26/01/2026
Éditeur
Georg Thieme Verlag KG
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • KU Leuven pays non établi dans la notice
    Université ou école supérieure
  • University Hospitals Leuven Department of Gastroenterology and Hepatology pays non établi dans la notice
    Université ou école supérieure

KU Leuven et Department of Gastroenterology and Hepatology — University Hospitals Leuven.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Esophageal Cancer Research and TreatmentEosinophilic EsophagitisEsophageal and GI Pathology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.